🔴 Solid Biosciences is trading 5.28% down in after-hours trading after releasing Q2 2026 financial results

Solid Biosciences is trading 5.28% down at $8.25 in after-hours trading after releasing second-quarter 2026 financial results after the August 6 session.

• Quarterly net loss was $54.8 million, compared with $39.5 million a year earlier, while operating expenses increased to $57.4 million.
• Liquidity totaled $377.7 million, with runway into mid-2028; continued equity financing, higher spending, and a larger share count may be weighing on after-hours sentiment.